Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2213
https://www.valueinhealthjournal.com/article/S1098-3015(15)04289-8/fulltext
Title : Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04289-8&doi=10.1016/j.jval.2015.09.2213
First page : A628
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 1631
Categories :
Tags :
Regions :
ViH Article Tags :